Literature DB >> 20884821

46-year-old man with treatment-resistant hypertension.

Nicholas M Orme1, Phil A Hart, Karen F Mauck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20884821      PMCID： PMC2947970          DOI： 10.4065/mcp.2009.0784

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  11 in total

1.  Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome.

Authors:  J W CONN
Journal:  J Lab Clin Med       Date:  1955-01

Review 2.  Primary aldosteronism: diagnostic and treatment strategies.

Authors:  Cecilia Mattsson; William F Young
Journal:  Nat Clin Pract Nephrol       Date:  2006-04

3.  Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.

Authors:  Paul Milliez; Xavier Girerd; Pierre-François Plouin; Jacques Blacher; Michel E Safar; Jean-Jacques Mourad
Journal:  J Am Coll Cardiol       Date:  2005-04-19       Impact factor: 24.094

4.  Primary aldosteronism: factors associated with normalization of blood pressure after surgery.

Authors:  A M Sawka; W F Young; G B Thompson; C S Grant; D R Farley; C Leibson; J A van Heerden
Journal:  Ann Intern Med       Date:  2001-08-21       Impact factor: 25.391

Review 5.  Primary aldosteronism: renaissance of a syndrome.

Authors:  William F Young
Journal:  Clin Endocrinol (Oxf)       Date:  2007-05       Impact factor: 3.478

6.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Circulation       Date:  2008-06-24       Impact factor: 29.690

7.  Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.

Authors:  Ellen D Burgess; Yves Lacourcière; Luis M Ruilope-Urioste; Suzanne Oparil; Jay H Kleiman; Scott Krause; Barbara Roniker; Clement Maurath
Journal:  Clin Ther       Date:  2003-09       Impact factor: 3.393

8.  Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.

Authors:  Asterios Karagiannis; Konstantinos Tziomalos; Athanasios Papageorgiou; Anna I Kakafika; Efstathios D Pagourelias; Panagiotis Anagnostis; Vasilios G Athyros; Dimitri P Mikhailidis
Journal:  Expert Opin Pharmacother       Date:  2008-03       Impact factor: 3.889

9.  Primary aldosteronism and hypertensive disease.

Authors:  Lorena Mosso; Cristian Carvajal; Alexis González; Adolfo Barraza; Fernando Avila; Joaquín Montero; Alvaro Huete; Alessandra Gederlini; Carlos E Fardella
Journal:  Hypertension       Date:  2003-06-09       Impact factor: 10.190

Review 10.  Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism.

Authors:  Marlies J E Kempers; Jacques W M Lenders; Lieke van Outheusden; Gert Jan van der Wilt; Leo J Schultze Kool; Ad R M M Hermus; Jaap Deinum
Journal:  Ann Intern Med       Date:  2009-09-01       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.